Supply of Valsartan/Hydrochlorothiazide 320-25 mg Tablets (90-count bottles)

The contract obligates the manufacturer to produce and supply higher-dose Valsartan/Hydrochlorothiazide 320-25 mg tablets in 90-count bottles, fully compliant with FDA regulations, current Good Manufacturing Practices, and the Drug Supply Chain Security Act. All production must meet stringent quality and traceability standards to ensure patient safety and regulatory compliance throughout the supply chain. The product is intended for delivery to Department of Defense prime vendors serving DLA Troop Support, with no set-aside provisions specified, and must be packaged and shipped according to exact specifications outlined in the agreement. The solicitation is classified as a subcontract under NAICS code 325412 for pharmaceutical manufacturing, with a response deadline of August 13, 2026, at 7:00 PM Eastern Time, and was posted on July 13, 2026. The place of performance and point of contact details are not provided, but performance is required to support federal healthcare logistics through DLA Troop Support, a component of the Department of Defense. The contract does not include details on quantity, pricing, or payment terms, and interested parties must refer to the official SAM.gov posting for full submission requirements and technical specifications.